Capricor Therapeutics

Update in progress

CAPR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Capricor Therapeutics is a clinical-stage biotech focused on cell- and exosome-based therapies for Duchenne muscular dystrophy (DMD) and other unmet needs in the United States. Its lead candidate, Deramiocel, allogeneic cardiosphere-derived cells, is in Phase 3 for DMD. It also develops Exosome protein-based vaccines and the StealthX exosome platform, in preclinical stages, plus StealthX for RNA, protein, and small molecules in Phase 1. It has licenses with Johns Hopkins, University of Rome, Cedars-Sinai, and Life Technologies, and is based in San Diego, founded in 2005.

Company score

Sentiment: -0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive